<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="201866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461851</url>
  </required_header>
  <id_info>
    <org_study_id>0609001823</org_study_id>
    <nct_id>NCT00461851</nct_id>
  </id_info>
  <brief_title>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma</brief_title>
  <official_title>A Phase II, Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, nonrandomized multicenter study designed to evaluate time to progression
      and response proportion of patients with advanced or metastatic transitional cell carcinoma
      of bladder receiving 6 cycles of gemcitabine, carboplatin and sorafenib and then maintenance
      sorafenib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Time to Disease Progression in Patients With Advanced/Metastatic TCC Treated With the Combination of Sorafenib, Gemcitabine, and Carboplatin.</measure>
    <time_frame>Upon completion of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Overall Safety and Tolerability of Combination Therapy With Sorafenib, Gemcitabine and Carboplatin</measure>
    <time_frame>Upon completion of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Define the Proportion of Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Bladder That Achieve a Complete or Partial Response to the Combination Therapy With Sorafenib, Gemcitabine, and Carboplatin.</measure>
    <time_frame>Upon completion of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy plus sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.</description>
    <arm_group_label>Chemotherapy plus sorafenib</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be given on day 1 to an AUC of 5.</description>
    <arm_group_label>Chemotherapy plus sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib will be administered orally daily on days 2-19 at 400 mg bid</description>
    <arm_group_label>Chemotherapy plus sorafenib</arm_group_label>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic documentation of diagnosis of transitional cell carcinoma of the bladder,
             urethra, ureter, or renal pelvis

          -  Unresectable, locally advanced or metastatic disease

          -  CrCl ≥ 60 ml/min or serum creatinine &lt; 1.5

          -  ≥ 4 weeks since prior RT

          -  ECOG Performance Status of 0 or 1 (Appendix I)

          -  Age ≥ 18 years of age

          -  Women of childbearing potential and men must agree to use adequate contraception
             (barrier method of birth control) prior to study entry and for the duration of study
             participation. Men and women should use adequate birth control for at least 2 weeks
             after the last administration of sorafenib.

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of treatment

          -  Ability to understand and the willingness to sign a written informed consent. A
             signed informed consent must be obtained prior to any study specific procedures.

          -  Adequate bone marrow, liver and renal function as assessed by the following:

               -  Hemoglobin &gt; 9.0 g/dl

               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

               -  Platelet count ≥ 100,000/mm3

               -  Total bilirubin ≤ 1.5 times ULN

          -  ALT and AST ≤ 2.5 times the ULN ( ≤ 5 x ULN for patients with liver involvement)

          -  INR &lt; 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation
             treatment with an agent such as warfarin or heparin may be allowed to participate.
             For patients on warfarin, the INR should be measured prior to initiation of sorafenib
             and monitored at least weekly, or as defined by the local standard of care, until INR
             is stable.

        Exclusion Criteria:

          -  Prior treatment with systemic chemotherapy (prior intravesical chemotherapy is
             permitted, and adjuvant therapy is permitted if &gt; 12 months have lapsed)

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study

          -  Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have
             unstable angina (anginal symptoms at rest) or new onset angina (began within the last
             3 months) or myocardial infarction within the past 6 months.

          -  History of stroke within six months

          -  Clinically significant peripheral vascular disease

          -  Known brain metastasis. Patients with neurological symptoms must undergo a CT
             scan/MRI of the brain to exclude brain metastasis.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic
             pressure &gt; 90 mmHg, despite optimal medical management.

          -  Sorafenib is contraindicated in patients with known severe hypersensitivity to
             sorafenib or any of the excipients.

          -  Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.

          -  Active clinically serious infection &gt; CTCAE Grade 2.

          -  Thrombolytic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks within the past 6 months

          -  Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
             study drug

          -  Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Evidence or history of bleeding diathesis or coagulopathy

          -  Major surgery, significant traumatic injury within 4 weeks of first study drug

          -  Use of St. John's Wort or rifampin (rifampicin)

          -  Known or suspected allergy to sorafenib or any agent given in the course of this
             trial

          -  Any condition that impairs patient's ability to swallow whole pills

          -  Any malabsorption problem

          -  Anticipation of need for major surgical procedure during the course of the study

          -  Pregnant (positive pregnancy test) or lactating

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within 6 months prior to Day 0

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Inability to comply with study and/or follow-up procedures

          -  History of persistent gross hematuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hari Deshpande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University, Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 12, 2016</lastchanged_date>
  <firstreceived_date>April 16, 2007</firstreceived_date>
  <firstreceived_results_date>September 12, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced/Metastatic Bladder Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy Plus Sorafenib</title>
          <description>Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
Gemcitabine: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Carboplatin: Carboplatin will be given on day 1 to an AUC of 5.
Sorafenib: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy Plus Sorafenib</title>
          <description>Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
Gemcitabine: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Carboplatin: Carboplatin will be given on day 1 to an AUC of 5.
Sorafenib: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="47" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Time to Disease Progression in Patients With Advanced/Metastatic TCC Treated With the Combination of Sorafenib, Gemcitabine, and Carboplatin.</title>
        <time_frame>Upon completion of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy Plus Sorafenib</title>
            <description>Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
Gemcitabine: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Carboplatin: Carboplatin will be given on day 1 to an AUC of 5.
Sorafenib: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Time to Disease Progression in Patients With Advanced/Metastatic TCC Treated With the Combination of Sorafenib, Gemcitabine, and Carboplatin.</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="5.6" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Overall Safety and Tolerability of Combination Therapy With Sorafenib, Gemcitabine and Carboplatin</title>
        <time_frame>Upon completion of study</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Define the Proportion of Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Bladder That Achieve a Complete or Partial Response to the Combination Therapy With Sorafenib, Gemcitabine, and Carboplatin.</title>
        <time_frame>Upon completion of study</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy Plus Sorafenib</title>
          <description>Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
Gemcitabine: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Carboplatin: Carboplatin will be given on day 1 to an AUC of 5.
Sorafenib: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michael Hurwitz</name_or_title>
      <organization>Yale University Yale Cancer Center</organization>
      <phone>2037371600</phone>
      <email>Hari.deshpande@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
